EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or ...
Findings may support development of more refined personalized breast cancer risk prediction models for BRCA1 pathogenic ...
Rare diseases, defined in the U.S. as conditions affecting fewer than 200,000 people, can take years, if not decades, to ...
Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...
Scientists at the Baylor College of Medicine and collaborating institutions used complementary approaches that integrate exome sequencing and evolutionary action machine learning to identify protein ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
Agilent Technologies introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The new all-exon solutions incorporate the latest advances from Agilent Genomics, the ...
The optimising EXome PREnatal Sequencing Services (EXPRESS) policy report outlines actions to strengthen clinical implementation of, and further research on, prenatal exome sequencing services in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results